Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

BACKGROUND. Previous efforts to preserve β cell function in individuals with type 1 diabetes (T1D) have focused largely on the use of single immunomodulatory agents administered within 100 days of diagnosis. Based on human and preclinical studies, we hypothesized that a combination of low-dose anti-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Haller, Michael J., Gitelman, Stephen E., Gottlieb, Peter A., Michels, Aaron W., Rosenthal, Stephen M., Shuster, Jonathan J., Zou, Baiming, Brusko, Todd M., Hulme, Maigan A., Wasserfall, Clive H., Mathews, Clayton E., Atkinson, Mark A., Schatz, Desmond A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2014
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382237/
https://ncbi.nlm.nih.gov/pubmed/25500887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados